Verici Dx plc (LON:VRCI – Get Free Report) dropped 10.3% on Thursday . The stock traded as low as GBX 3.23 ($0.04) and last traded at GBX 3.25 ($0.04). Approximately 638,508 shares were traded during trading, a decline of 14% from the average daily volume of 741,081 shares. The stock had previously closed at GBX 3.63 ($0.05).
Verici Dx Stock Performance
The firm has a market capitalization of £7.88 million, a PE ratio of -162.50 and a beta of 1.59. The company has a debt-to-equity ratio of 4.65, a current ratio of 4.54 and a quick ratio of 8.49. The business has a 50-day simple moving average of GBX 3.63 and a 200-day simple moving average of GBX 4.79.
About Verici Dx
Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.
See Also
- Five stocks we like better than Verici Dx
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- 3 Reasons Micron Stock Is Deeply Undervalued Right Now
- Pros And Cons Of Monthly Dividend Stocks
- Inflation Persists, But So Do Stock Opportunities: Rally On
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Energy Transfer Fuels the Cloud: A Natural Gas Power Play
Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.
